Carbapenem Resistance Revisited: Reassessing Our Antibiotics of Choice

Universal and inclusive HIV prevention means that all roads lead to PrEP discussion! In this podcast, featuring audio from a live webinar, expert faculty from the National Clinician Consultation Center, Chris Bositis, MD, AAHIVS, and Carolyn Chu, MD, MSc, FAAFP, AAHIVS, share insights on the most common questions they receive about PrEP and HIV prevention.

The CDC characterized the 2025-2026 influenza season as moderate overall, but the burden in the United States was substantial, with suboptimal seasonal influenza vaccine uptake among adults and children. Stream this podcast, featuring audio from a live webinar led by experts Paul G. Auwaerter, MD, MBA, and Ravi Jhaveri, MD, FIDSA, FPIDS, FAAP, to help you optimize influenza vaccine uptake in your practice.

Mental health care is HIV care! Incorporating screening and treatment for mild to moderate cases of bipolar disorder, trauma, and personality disorders in HIV primary care can improve both mental health and HIV-related outcomes, but it is also important to know when to refer or escalate. Featuring audio from a live webinar presented by experts Kathleen Page, MD, and Glenn Treisman, MD, PhD, this case-based virtual Grand Rounds series explores practical strategies for integrating routine mental health screening, referral, and management into HIV care to support engagement, ART adherence, and overall outcomes for people living with HIV.

Achieving virologic suppression is still the primary goal of HIV management, but there are many reasons to consider switching a suppressive ART regimen that have nothing to do with resistance or treatment failure, including newly approved regimens, personal preference, changes in comorbidities or coinfections, and quality of life. Listen in to learn practical strategies for proactive ART switch and learn how to guide clinical conversations about ART switch in this podcast, featuring audio from a live webinar hosted by National Clinician Consultation Center experts Daniel Moring-Parris, MD, AAHIVS, and Cristina Gruta, PharmD, AAHIVP.

At the 26th International AIDS Conference (AIDS 2026), some of the most important topics included new clinical trial and real-world data for available and emerging initial antiretroviral therapy (ART) regimens and long-acting options for ART and HIV pre-exposure prophylaxis (PrEP). In this podcast featuring audio from a live webinar, experts Claudia P. Cortes, MD, and Chloe Orkin, MBChB, FRCP, MD, give their perspectives.